Volume Reduction Technology... Webinar Recording (Feb 8 2012)
Volume reduction technology for large scale harvest or post-thaw manipulation of cellular therapeutics
Organized by the Commercialization Committee
Chair: Wouter Van't Hof, Director of Regenerative Medicine, Athersys Inc.
Dr. Harvey Brandwein, Pall Life Sciences, Vice President
Dr. John Chapman, Stem Cell Partners
About the Webinar:
The manufacturing processes for cell therapy products (CTPs) can face a variety of challenges, including variability in the nature, source and intended uses of the products. To make the process amenable to later stage clinical testing and the product commercially viable, scale-up routinely receives significant emphasis in development of manufacturing platforms. Today we will discuss two examples of available of new technologies for cell product manipulation that come into play during and after successful scale up, namely at the time of banking and at the time of administration.
Filtration technology has originally focused mainly on isolation of biologicals such as monoclonal antibodies away from the cells that produce them. With cell therapy coming of age, there is increased interest in adapting filtration procedures towards isolation and purification of the cells themselves as the therapeutic product, bringing along its own specific set of opportunity and challenges.
In addition, new technologies are required for manipulation of large cell amounts thawed from cryo-preserved product doses, to enable routine clinical administration in a safe, reproducible and relatively quick and simple manner. New point of care devices are in development to permit harvesting, washing and concentration of large quantities of cells into any desired configuration.
This product is a downloadable PDF and provides a link to an mp4 video recording of the webinar.